24023-71-0

Basic information

• Product Name: 2-CHLOROMETHYL-5-(4-METHOXYPHENYL)-1,2,4-OXADIAZOLE
• Synonyms: BUTTPARK 96\57-63;ASISCHEM D38787;2-CHLOROMETHYL-5-(4-METHOXYPHENYL)-1,2,4-OXADIAZOLE;2-(CHLOROMETHYL)-5-(4-METHOXYPHENYL)-1,3,4-OXADIAZOLE;TIMTEC-BB SBB005576;2-CHLOROMETHYL-5-(4-METHOXYPHENYL)-1,2,4- OXADIAZOLE 98%;2-Chloromethyl-5-(4-methoxyphenyl)-1,3,4-oxadiazole,98%;4-[5-(Chloromethyl)-1,3,4-oxadiazol-2-yl]anisole
• CAS NO: 24023-71-0
• Molecular Formula: C₁₀H₉ClN₂O₂
• Molecular Weight: 224.64
• Mol File: 24023-71-0.mol
• Article Data: 16

Chemical Properties

• Melting Point: 91-95 °C
• Boiling Point: 354.9°Cat760mmHg
• Flash Point: 168.4°C
• Appearance: Light yellow/Crystalline Powder
• Density: 1.3919 (rough estimate)
• Vapor Pressure: 6.63E-05mmHg at 25°C
• Refractive Index: 1.5790 (estimate)
• CAS DataBase Reference: 2-CHLOROMETHYL-5-(4-METHOXYPHENYL)-1,2,4-OXADIAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLOROMETHYL-5-(4-METHOXYPHENYL)-1,2,4-OXADIAZOLE(24023-71-0)
• EPA Substance Registry System: 2-CHLOROMETHYL-5-(4-METHOXYPHENYL)-1,2,4-OXADIAZOLE(24023-71-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 37/39-26
• Hazardous Substances Data: 24023-71-0(Hazardous Substances Data)

Usage

Chemical Properties

light yellow crystalline powder

InChI:InChI=1/C10H9ClN2O2/c1-14-8-4-2-7(3-5-8)10-13-12-9(6-11)15-10/h2-5H,6H2,1H3

Upstream product

• 3290-99-1 4-methoxybenzoic acid hydrazide 
• 74974-54-2 2-chloro-1,1,1-trimethoxyethane 
• 100-09-4 4-methoxybenzoic acid 
• 94-30-4 ethyl 4-methoxybenzoate 
• 50677-25-3 PCM-0102115 

Relevant articles and documents

Syntheses and insecticidal activity of new 2-(5-(trifluoromethyl)pyridyloxymethyl)-1,3,4-oxadiazoles

Eight 2-(5-(trifluoromethyl)pyridyloxymethyl)-1,3,4-oxadiazoles have been designed and synthesized by four-step synthetic route. The structures of all new compounds were confirmed by 1H NMR, mass and HR mass spectroscopy. The preliminary bioass

Synthesis and biological evaluation of honokiol derivatives bearing 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)oxazol-2(3h)-ones as potential viral entry inhibitors against sars-cov-2

The 2019 coronavirus disease (COVID-19) caused by SARS-CoV-2 virus infection has posed a serious danger to global health and the economy. However, SARS-CoV-2 medications that are specific and effective are still being developed. Honokiol is a bioactive component from Magnoliae officinalis Cortex with damp-drying effect. To develop new potent antiviral molecules, a series of novel honokiol analogues were synthesized by introducing various 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)oxazol-2(3H)-ones to its molecule. In a SARS-CoV-2 pseudovirus model, all honokiol derivatives were examined for their antiviral entry activities. As a result, 6a and 6p demonstrated antiviral entry effect with IC50 values of 29.23 and 9.82 μM, respectively. However, the parental honokiol had a very weak antiviral activity with an IC50 value more than 50 μM. A biolayer interfero-metry (BLI) binding assay and molecular docking study revealed that 6p binds to human ACE2 protein with higher binding affinity and lower binding energy than the parental honokiol. A competitive ELISA assay confirmed the inhibitory effect of 6p on SARS-CoV-2 spike RBD’s binding with ACE2. Importantly, 6a and 6p (TC50 > 100 μM) also had higher biological safety for host cells than honokiol (TC50 of 48.23 μM). This research may contribute to the discovery of potential viral entrance inhibitors for the SARS-CoV-2 virus, although 6p’s antiviral efficacy needs to be validated on SARS-CoV-2 viral strains in a biosafety level 3 facility.

Oxazole ring-containing honokiol thioether derivative and preparation method and application thereof

The invention discloses an oxazole ring-containing honokiol thioether derivative, a preparation method thereof and application of the oxazole ring-containing honokiol thioether derivative as an alpha-glucosidase inhibitor, the chemical structure of the oxazole ring-containing honokiol thioether derivative is shown as a general formula (I), and R is selected from non-substituted or substituted phenyl. Compared with the prior art, the invention provides the novel honokiol thioether derivative containing the oxazole ring, and the honokiol thioether derivative containing the oxazole ring has good inhibitory activity on alpha-glucosidase, provides more possibilities for treating diabetes, and is expected to be used for preparing novel candidate drug molecules for treating diabetes. In addition, the preparation process is simple, the cost is low, and the yield is high.

Design and synthesis of new norfloxacin-1,3,4-oxadiazole hybrids as antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA)

Toward the search of new antibacterial agents to control methicillin-resistant Staphylococcus aureus (MRSA), a class of new norfloxacin-1,3,4-oxadiazole hybrids were designed and synthesized. Antibacterial activities against drug-sensitive bacteria S. aureus and clinical drug resistant isolates of MRSA were evaluated. Compound 5k exhibited excellent antibacterial activities against S. aureus (MIC: 2 μg/mL) and MRSA1–3 (MIC: 0.25–1 μg/mL). The time-kill kinetics demonstrated that compound 5k had an advantage over commonly used antibiotics vancomycin in killing S. aureus and MRSA. Moreover, compound 5k could inhibit the bacteria and destroy their membranes in a short time, and showed very low cytotoxicity to NRK-52E cells. Some interesting structure-activity relationships (SARs) were also discussed. These results indicated that these norfloxacin-1,3,4-oxadiazole hybrids could be further developed into new antibacterial agents against MRSA.